Open for bids Tender Germany ICB TOT Ref. 152326579

Conclusion not Excluding Drug Discount Agreement. Tender - 152326579

Tender notice from Germany, published on 11 Nov 2026.

Executive Summary

Title/Summary: Tender for non-exclusive discount agreements for the drug Ranibizumab FER under an Open-House model by AOK PLUS in Erfurt, Germany. The tender is referenced as 164/2026-OH and will conclude on December 31, 2027.

Scope Of Work: The tender involves establishing non-exclusive discount agreements for the drug Ranibizumab, provided as a 10 mg/ml injection solution. This will be done through an Open-House model, allowing all interested pharmaceutical companies to participate as long as they meet the eligibility criteria. The quantity of drugs ordered is uncertain, as it depends on demand and other factors. Interested companies must apply for access to the project documents via the German Procurement Portal (DTVP), and all communications will be conducted electronically.

Qualification Criterion: Bidders must be pharmaceutical companies capable of meeting the participation requirements outlined in the project documents available on the DTVP. They are required to maintain confidentiality regarding the content of the participation documents and must destroy all documents if they choose not to participate. Applications can be submitted starting December 2, 2026, and late submissions will be considered in the next application period.

Key facts

Summary
Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Ranibizumab Fer (Atc Code According to Who: S01la04)
TOT Ref. No.
152326579
Document Ref. No.
Login to see
Country
Germany
Notice type
Tender
Competition
ICB
Publication date
11 Nov 2026
Bid deadline
31 Dec 2027
EMD
Refer Document
Tender value
Refer Document
Purchaser ownership
Public
Financier
Self Financed

CPV classification

Purchaser details

Purchaser contact is for registered users

Login to see details

Tender details

Tender details are for registered users

Login to see details

Documents

Tender Notice
Login to view

Similar tenders

Germany Public Procurement Intelligence

Frequently asked questions

The last date to submit a bid for Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Ranibizumab Fer (Atc Code According to Who: S01la04) is 31 Dec 2027. Submit before this date to be considered.

This tender has been issued by AOK PLUS - THE HEALTH INSURANCE FUND FOR SAXONY AND THURINGIA in Germany.

The tender value is not disclosed; please refer to the tender document. EMD / bid security details are provided in the tender document.

This tender is Self Financed

The tender is classified under the following CPV code(s): 33600000 - Pharmaceutical products.

The tender notice and related documents are listed in the Documents section above. Select a document to view or download it. Please log in or register to access the documents. If you cannot find additional documents in the Documents section, please log in to your account and Send Document Request from your account section.

The TendersOnTime reference is 152326579. The purchaser document reference is available after login.

See the Similar Tenders section on this page or browse other tenders from Germany.

This tender falls under Materials and Products, Technology and Equipment in Germany. Suppliers in these sectors can track similar Germany tenders using CPV-based alerts.